{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:36:14Z","timestamp":1791920174763,"version":"4.3.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T00:00:00Z","timestamp":1643241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Obesity and eating disorders can present together, and pose diagnostic and therapeutic challenges to the clinician. Generally, lifestyle interventions alone for the treatment of obesity have modest long-term effectiveness. Phentermine\u2013topiramate extended release is a relatively new medication approved for weight reduction. Sleep-related eating disorder is a rare condition that is often underdiagnosed. Both conditions are chronic and require long-term management. There is no definitive treatment for sleep-related eating disorder, and therapeutic options are based on case reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 35-year-old Caucasian\u00a0male with a body mass index of 41.7\u00a0kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      presented for obesity treatment. History revealed nocturnal episodes of hyperphagia associated with amnesia of overeating and other features of sleep-related eating disorder. Treatment was initiated with phentermine\u2013topiramate extended release. Five\u00a0months later he lost 5% of his body weight and demonstrated resolution of sleep-related eating disorder behaviors. He reported no adverse side effects. Upon self-discontinuation of the medication, his eating disorder recurred.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Clinicians intending to help patients reduce body weight should screen for nocturnal eating and other eating disorders. Sleep-related eating disorder can be associated with significant morbidity and excess weight. Patients report adverse effects on quality of life as a result. Phentermine\u2013topiramate extended release may be a good therapeutic option for patients presenting with comorbid obesity and sleep-related eating disorder. More research is needed to explore the efficacy and safety in this patient population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13256-021-03250-1","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T19:03:36Z","timestamp":1643223816000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phentermine\u2013topiramate extended release for the dual treatment of obesity and sleep-related eating disorder: a case report"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9332-7069","authenticated-orcid":false,"given":"Eduardo","family":"Grunvald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"DeConde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,27]]},"reference":[{"issue":"1","key":"3250_CR1","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/nyas.13467","volume":"1411","author":"C McCuen-Wurst","year":"2018","unstructured":"McCuen-Wurst C, Ruggieri M, Allison KC. Disordered eating and obesity: associations between binge-eating disorder, night-eating syndrome, and weight-related comorbidities. Ann N Y Acad Sci. 2018;1411(1):96\u2013105.","journal-title":"Ann N Y Acad Sci"},{"key":"3250_CR2","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/obr.12551","volume":"18","author":"GA Bray","year":"2017","unstructured":"Bray GA, Kim KK, Wilding JPH. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obes Rev. 2017;18:715\u201323.","journal-title":"Obes Rev"},{"issue":"3","key":"3250_CR3","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.biopsych.2006.03.040","volume":"61","author":"JI Hudson","year":"2007","unstructured":"Hudson JI, Hiripi E, Pope HG, Kessler RC. The prevalence and correlates of eating disorders in the national comorbidity survey replication. Biol Psychiatry. 2007;61(3):348\u201358.","journal-title":"Biol Psychiatry"},{"issue":"5","key":"3250_CR4","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/oby.2008.676","volume":"17","author":"S Tholin","year":"2009","unstructured":"Tholin S, Lindroos A, Tynelius P, \u00c5kerstedt T, Stunkard AJ, Bulik CM, et\u00a0al. Prevalence of night eating in obese and nonobese twins. Obesity. 2009;17(5):1050\u20135.","journal-title":"Obesity"},{"issue":"7","key":"3250_CR5","first-page":"19","volume":"6","author":"MJ Howell","year":"2007","unstructured":"Howell MJ, Schenck C, Crow SJ. Curbing nocturnal binges in sleep-related eating disorder. Curr Psychiatry. 2007;6(7):19\u201324.","journal-title":"Curr Psychiatry"},{"issue":"6","key":"3250_CR6","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1111\/pcn.12263","volume":"69","author":"Y Inoue","year":"2014","unstructured":"Inoue Y. Sleep-related eating disorder and its associated conditions. Psychiatry Clin Neurosci. 2014;69(6):309\u201320.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"6","key":"3250_CR7","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1017\/S0033291799008272","volume":"29","author":"JW Winkelman","year":"1999","unstructured":"Winkelman JW, Herzog DB, Fava M. The prevalence of sleep-related eating disorder in psychiatric and non-psychiatric populations. Psychol Med. 1999;29(6):1461\u20136.","journal-title":"Psychol Med"},{"key":"3250_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11940-015-0361-6","volume":"17","author":"G Chiaro","year":"2015","unstructured":"Chiaro G, Caletti MT, Provini F. Treatment of sleep-related eating disorder. Curr Treat Options Neurol. 2015;17:1\u201311.","journal-title":"Curr Treat Options Neurol"},{"key":"3250_CR9","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.4088\/JCP.v67n1109","volume":"67","author":"JW Winkelman","year":"2006","unstructured":"Winkelman JW. Efficacy and tolerability of open-label topiramate in the treatment of sleep-related eating disorder: a retrospective case series. J Clin Psychiatry. 2006;67:1729\u201334.","journal-title":"J Clin Psychiatry"},{"issue":"3","key":"3250_CR10","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/S1389-9457(03)00060-1","volume":"4","author":"JW Winkelman","year":"2003","unstructured":"Winkelman JW. Treatment of nocturnal eating syndrome and sleep-related eating disorder with topiramate. Sleep Med. 2003;4(3):243\u20136.","journal-title":"Sleep Med"},{"issue":"11","key":"3250_CR11","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1038\/sj.ijo.0802783","volume":"28","author":"J Wilding","year":"2004","unstructured":"Wilding J, Gaal LV, Rissanen A, Vercruysse F, Fitchet M. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes. 2004;28(11):1399\u2013410.","journal-title":"Int J Obes"},{"key":"3250_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1111\/j.1463-1326.2006.00618.x","volume":"9","author":"K Stenl\u00f6f","year":"2007","unstructured":"Stenl\u00f6f K, R\u00f6ssner S, Vercruysse F, Kumar A, Fitchet M, Sj\u00f6str\u00f6m L. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diab Obes Metab. 2007;9:360\u20138.","journal-title":"Diab Obes Metab."},{"issue":"2","key":"3250_CR13","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.amjcard.2005.03.053","volume":"96","author":"S Tonstad","year":"2005","unstructured":"Tonstad S, Tykarski A, Weissgarten J, Ivleva A, Levy B, Kumar A, et\u00a0al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96(2):243\u201351.","journal-title":"Am J Cardiol"},{"issue":"2","key":"3250_CR14","doi-asserted-by":"publisher","first-page":"297","DOI":"10.3945\/ajcn.111.024927","volume":"95","author":"WT Garvey","year":"2012","unstructured":"Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et\u00a0al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297\u2013308.","journal-title":"Am J Clin Nutr"},{"issue":"17","key":"3250_CR15","first-page":"1566","volume":"170","author":"Look AHEAD Research Group","year":"2010","unstructured":"Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus. Arch Intern Med. 2010;170(17):1566\u201375.","journal-title":"Arch Intern Med"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-021-03250-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-021-03250-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T19:03:42Z","timestamp":1643223822000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-021-03250-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,27]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3250"],"URL":"https:\/\/doi.org\/10.1186\/s13256-021-03250-1","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,27]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a case report, the Human Research Protections Program at the University of California San Diego has confirmed that no ethical approval is required. This report does not include any identifying information of the patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EG has received consulting fees from Novo Nordisk, Currax Pharmaceuticals, and Gelesis, Inc. He has also received research support from the Obesity Treatment Foundation (Grant No OTF001) and Litwin IBD Pioneers Program, Crohn\u2019s and Colitis Foundation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34"}}